Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Associated Therapies: -

Clinical Trials

A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Phase 4

Completed

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: bendamustine
Drug: chlorambucil
Drug: rituximab [MabThera/Rituxan]

First Posted Date: 2010-01-26

Last Posted Date: 2015-06-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 357

Registration Number: NCT01056510

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bendamustine
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2010-01-26

Last Posted Date: 2017-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 59

Registration Number: NCT01056276

Locations: 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸
Los Robles Hospital and Medical Center, Thousand Oaks, California, United States
🇺🇸
Florida Cancer Specialists, Ft. Myers, Florida, United States

and more 10 locations

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: bendamustine hydrochloride
Drug: lenalidomide
Drug: dexamethasone

First Posted Date: 2010-01-15

Last Posted Date: 2020-02-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 70

Registration Number: NCT01049945

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 2 locations

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Phase 1

Completed

Conditions: Myeloma

Interventions: Drug: Bendamustine
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Aspirin
Drug: Prophylaxis
Drug: Antibiotic
Other: Biweekly Follow Up
Other: Cyclical Follow Up
Other: Restaging
Other: Post-Treatment Follow Up

First Posted Date: 2010-01-05

Last Posted Date: 2017-07-31

Lead Sponsor: Robert Redner, MD

Target Recruit Count: 29

Registration Number: NCT01042704

Locations: 🇺🇸
UPMC Cancer Centers - Arnold Palmer at Mountain View, Greensburg, Pennsylvania, United States
🇺🇸
UPMC Cancer Centers - Arnold Palmer at Oakbrook, Greensburg, Pennsylvania, United States
🇺🇸
Hematology/Oncology - Private Practice, McKeesport, Pennsylvania, United States

and more 19 locations

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Bendamustine
Drug: Bortezomib
Drug: Rituximab

First Posted Date: 2009-12-10

Last Posted Date: 2016-08-19

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 55

Registration Number: NCT01029730

Locations: 🇺🇸
Florida Cancer Specialists, Ft. Myers, Florida, United States
🇺🇸
Hematology Oncology of the North Shore, Skokie, Illinois, United States
🇺🇸
Holy Cross Hospital, Ft. Lauderdale, Florida, United States

and more 17 locations

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

Early Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2009-12-01

Last Posted Date: 2017-01-10

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 17

Registration Number: NCT01022021

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Phase 3

Completed

Conditions: Marginal Zone Lymphomas
Non-Hodgkin Lymphomas
Follicular Lymphomas
Immunocytomas
Lymphocytic Lymphomas

Interventions: Drug: Standard chemotherapy CHOP + Ritiximab
Drug: Bendamustine

First Posted Date: 2009-10-07

Last Posted Date: 2024-08-22

Lead Sponsor: University of Giessen

Target Recruit Count: 549

Registration Number: NCT00991211

Locations: 🇩🇪
StiL Head Office; Justus-Liebig-University, Giessen, Germany

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bendamustine hydrochloride
Drug: lenalidomide

First Posted Date: 2009-10-01

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 49

Registration Number: NCT00987493

Locations: 🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Stadtspital Triemli, Zürich, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland

and more 13 locations

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: bendamustine hydrochloride

First Posted Date: 2009-09-25

Last Posted Date: 2014-03-12

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 50

Registration Number: NCT00984542

Locations: 🇺🇸
Hardin Memorial Hosptial, Elizabethtown, Kentucky, United States
🇺🇸
Jackson-Madison County Hospital, Jackson, Tennessee, United States
🇺🇸
Baptist Regional Cancer Center at Baptist Riverside, Knoxville, Tennessee, United States

and more 3 locations

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab
Drug: Lenalidomide

First Posted Date: 2009-09-10

Last Posted Date: 2019-12-02

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 34

Registration Number: NCT00974233

Locations: 🇺🇸
Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States
🇺🇸
Gundersen Clinic, La Crosse, Wisconsin, United States
🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy